Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/sorrento-therapeutics-inc-srne-financial-n-strategic-swot-analysis-review_en.gif)
Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis pain and autoimmune diseases. The company’s immunotherapy pipeline portfolio comprises of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops, Covishield among others for the treatment of COVID-19. Its marketed product include, ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc Key Recent Developments
Apr 05,2021: Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
Mar 05,2021: Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
Feb 08,2021: Sorrento announces subsidiary company - ADNAB - to develop and commercialize ADNAB platform products for hematological malignancies and solid tumors based on an exclusive technology license from the Mayo Clinic
Oct 16,2020: Sorrento Therapeutics to purchase ACEA Therapeutics
Oct 09,2020: Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis pain and autoimmune diseases. The company’s immunotherapy pipeline portfolio comprises of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops, Covishield among others for the treatment of COVID-19. Its marketed product include, ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc Key Recent Developments
Apr 05,2021: Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
Mar 05,2021: Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
Feb 08,2021: Sorrento announces subsidiary company - ADNAB - to develop and commercialize ADNAB platform products for hematological malignancies and solid tumors based on an exclusive technology license from the Mayo Clinic
Oct 16,2020: Sorrento Therapeutics to purchase ACEA Therapeutics
Oct 09,2020: Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Sorrento Therapeutics Inc - Key Facts
Sorrento Therapeutics Inc - Key Employees
Sorrento Therapeutics Inc - Key Employee Biographies
Sorrento Therapeutics Inc - Major Products and Services
Sorrento Therapeutics Inc - History
Sorrento Therapeutics Inc - Company Statement
Sorrento Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sorrento Therapeutics Inc - Business Description
Business Segment: Scilex
Overview
Performance
Business Segment: Sorrento Therapeutics
Overview
Performance
R&D Overview
Sorrento Therapeutics Inc - Corporate Strategy
Sorrento Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sorrento Therapeutics Inc - Strengths
Sorrento Therapeutics Inc - Weaknesses
Sorrento Therapeutics Inc - Opportunities
Sorrento Therapeutics Inc - Threats
Sorrento Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sorrento Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 05, 2021: Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
Feb 08, 2021: Sorrento announces subsidiary company - ADNAB - to develop and commercialize ADNAB platform products for hematological malignancies and solid tumors based on an exclusive technology license from the Mayo Clinic
Oct 09, 2020: Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Oct 04, 2020: Sorrento to host a R&D day to showcase covid-19 product pipeline
Sep 28, 2020: Sorrento releases preclinical data for STI-1499 (COVI-Guard) and STI-2020 (COVI-AMG), potent neutralizing antibodies against SARS-CoV-2
Aug 21, 2020: Sorrento to merge with gene-encoded therapies firm SmartPharm
Aug 18, 2020: Sorrento Therapeutics : Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jun 12, 2020: Sorrento announces full repayment of outstanding term loans
May 11, 2020: Sorrento, Mount Sinai to develop antibody cocktail against Covid-19
Apr 30, 2020: Sorrento Therapeutics took $2-5 million PPP government loan for COVID-19-struck small businesses, FOIA request shows
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Sorrento Therapeutics Inc - Key Facts
Sorrento Therapeutics Inc - Key Employees
Sorrento Therapeutics Inc - Key Employee Biographies
Sorrento Therapeutics Inc - Major Products and Services
Sorrento Therapeutics Inc - History
Sorrento Therapeutics Inc - Company Statement
Sorrento Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sorrento Therapeutics Inc - Business Description
Business Segment: Scilex
Overview
Performance
Business Segment: Sorrento Therapeutics
Overview
Performance
R&D Overview
Sorrento Therapeutics Inc - Corporate Strategy
Sorrento Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sorrento Therapeutics Inc - Strengths
Sorrento Therapeutics Inc - Weaknesses
Sorrento Therapeutics Inc - Opportunities
Sorrento Therapeutics Inc - Threats
Sorrento Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sorrento Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 05, 2021: Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
Feb 08, 2021: Sorrento announces subsidiary company - ADNAB - to develop and commercialize ADNAB platform products for hematological malignancies and solid tumors based on an exclusive technology license from the Mayo Clinic
Oct 09, 2020: Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
Oct 04, 2020: Sorrento to host a R&D day to showcase covid-19 product pipeline
Sep 28, 2020: Sorrento releases preclinical data for STI-1499 (COVI-Guard) and STI-2020 (COVI-AMG), potent neutralizing antibodies against SARS-CoV-2
Aug 21, 2020: Sorrento to merge with gene-encoded therapies firm SmartPharm
Aug 18, 2020: Sorrento Therapeutics : Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jun 12, 2020: Sorrento announces full repayment of outstanding term loans
May 11, 2020: Sorrento, Mount Sinai to develop antibody cocktail against Covid-19
Apr 30, 2020: Sorrento Therapeutics took $2-5 million PPP government loan for COVID-19-struck small businesses, FOIA request shows
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Sorrento Therapeutics Inc, Key Facts
Sorrento Therapeutics Inc, Key Employees
Sorrento Therapeutics Inc, Key Employee Biographies
Sorrento Therapeutics Inc, Major Products and Services
Sorrento Therapeutics Inc, History
Sorrento Therapeutics Inc, Subsidiaries
Sorrento Therapeutics Inc, Joint Venture
Sorrento Therapeutics Inc, Key Competitors
Sorrento Therapeutics Inc, Ratios based on current share price
Sorrento Therapeutics Inc, Annual Ratios
Sorrento Therapeutics Inc, Annual Ratios (Cont...1)
Sorrento Therapeutics Inc, Annual Ratios (Cont...2)
Sorrento Therapeutics Inc, Interim Ratios
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sorrento Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Sorrento Therapeutics Inc, Key Facts
Sorrento Therapeutics Inc, Key Employees
Sorrento Therapeutics Inc, Key Employee Biographies
Sorrento Therapeutics Inc, Major Products and Services
Sorrento Therapeutics Inc, History
Sorrento Therapeutics Inc, Subsidiaries
Sorrento Therapeutics Inc, Joint Venture
Sorrento Therapeutics Inc, Key Competitors
Sorrento Therapeutics Inc, Ratios based on current share price
Sorrento Therapeutics Inc, Annual Ratios
Sorrento Therapeutics Inc, Annual Ratios (Cont...1)
Sorrento Therapeutics Inc, Annual Ratios (Cont...2)
Sorrento Therapeutics Inc, Interim Ratios
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sorrento Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Sorrento Therapeutics Inc, Performance Chart (2016 - 2020)
Sorrento Therapeutics Inc, Ratio Charts
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Sorrento Therapeutics Inc, Performance Chart (2016 - 2020)
Sorrento Therapeutics Inc, Ratio Charts
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021